IDEX Biometrics extraordinary general meeting held on 23 Sep 2024

GlobeNewswire
2024-09-23

IDEX Biometrics ASA held an extraordinary general meeting on 23 September 2024. 87.2 million shares or 25.7% of the share capital was represented at the meeting.

The authorisation to the board to issue new shares, was approved by the extraordinary general meeting. The board will apply this authorization to issue the Tranche 1 Shares as disclosed in connection with the private placement on 16 September 2024: https://newsweb.oslobors.no/message/627919 .

For the avoidance of doubt, the issue of Tranche 2 Shares and the Subsequent Offering will be presented to the extraordinary general meeting on 9 October 2024; https://newsweb.oslobors.no/message/627919 .

For further information contact:
Marianne Bøe, Head of investor relations
E-mail: marianne.boe@idexbiometrics.com
Tel: +47 918 00186


About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.

For more information, visit www.idexbiometrics.com

About this notice
This notice was issued by Erling Svela, Vice president of finance, on 23 June 2024 at 13:35 CET on behalf of IDEX Biometrics ASA. This information is subject to disclosure pursuant to Euronext Oslo Børs rule book, and also section 5‑8 of the Norwegian Securities Trading Act (STA) and published in accordance with section 5‑12 of the STA.


免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10